Hemorrhagic shock and resuscitation (HS/R)-induced injuries often result from trauma or severe blood loss and can quickly progress to organ failure. Researchers at Nationwide Children’s Hospital have developed a novel method for treating subjects at risk for HS/R by administering Heparin Binding-Epidermal Growth Factor (HB-EGF). Administration of HB-EGF protects intestinal epithelial and endothelial cells from HS/R-induced injury in a rat model. This novel method may have broad clinical availability for treating or preventing a range of intestinal injuries in pediatric and adult patients.